These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 12683425)

  • 21. [Safety of selective inhibitors of inducible cyclooxygenase-2 taken for a long period].
    Lamarque D
    Bull Cancer; 2004 May; 91 Spec No():S117-24. PubMed ID: 15239340
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of celecoxib and diclofenac on blood pressure, renal function, and vasoactive prostanoids in young and elderly subjects.
    Dilger K; Herrlinger C; Peters J; Seyberth HW; Schweer H; Klotz U
    J Clin Pharmacol; 2002 Sep; 42(9):985-94. PubMed ID: 12211224
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study.
    Singh G; Fort JG; Goldstein JL; Levy RA; Hanrahan PS; Bello AE; Andrade-Ortega L; Wallemark C; Agrawal NM; Eisen GM; Stenson WF; Triadafilopoulos G;
    Am J Med; 2006 Mar; 119(3):255-66. PubMed ID: 16490472
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A regional audit of the use of COX-2 selective non-steroidal anti-inflammatory drugs (NSAIDs) in rheumatology clinics in the West Midlands, in relation to NICE guidelines.
    Price-Forbes AN; Callaghan R; Allen ME; Rowe IF
    Rheumatology (Oxford); 2005 Jul; 44(7):921-4. PubMed ID: 15827035
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Blood pressure in Native Americans switched from celecoxib to rofecoxib.
    Fredy J; Diggins DA; Morrill GB
    Ann Pharmacother; 2005 May; 39(5):797-802. PubMed ID: 15797981
    [TBL] [Abstract][Full Text] [Related]  

  • 26. More pronounced inhibition of cyclooxygenase 2, increase in blood pressure, and reduction of heart rate by treatment with diclofenac compared with celecoxib and rofecoxib.
    Hinz B; Dormann H; Brune K
    Arthritis Rheum; 2006 Jan; 54(1):282-91. PubMed ID: 16385545
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug switching patterns among patients with rheumatoid arthritis and osteoarthritis using COX-2 specific inhibitors and non-specific NSAIDs.
    Zhao SZ; Wentworth C; Burke TA; Makuch RW
    Pharmacoepidemiol Drug Saf; 2004 May; 13(5):277-87. PubMed ID: 15133778
    [TBL] [Abstract][Full Text] [Related]  

  • 28. COX-1 and COX-2 inhibitors.
    Hawkey CJ
    Best Pract Res Clin Gastroenterol; 2001 Oct; 15(5):801-20. PubMed ID: 11566042
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Licofelone--clinical update on a novel LOX/COX inhibitor for the treatment of osteoarthritis.
    Alvaro-Gracia JM
    Rheumatology (Oxford); 2004 Feb; 43 Suppl 1():i21-5. PubMed ID: 14752172
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.
    Rahme E; Nedjar H
    Rheumatology (Oxford); 2007 Mar; 46(3):435-8. PubMed ID: 17255138
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk.
    Solomon DH; Avorn J; Stürmer T; Glynn RJ; Mogun H; Schneeweiss S
    Arthritis Rheum; 2006 May; 54(5):1378-89. PubMed ID: 16645966
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A comparison of adverse renovascular experiences among osteoarthritis patients treated with rofecoxib and comparator non-selective non-steroidal anti-inflammatory agents.
    Gertz BJ; Krupa D; Bolognese JA; Sperling RS; Reicin A
    Curr Med Res Opin; 2002; 18(2):82-91. PubMed ID: 12017215
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiovascular effects of selective cyclooxygenase-2 inhibitors.
    Krum H; Liew D; Aw J; Haas S
    Expert Rev Cardiovasc Ther; 2004 Mar; 2(2):265-70. PubMed ID: 15151474
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Celecoxib, a COX-2--specific inhibitor: the clinical data.
    Fort J
    Am J Orthop (Belle Mead NJ); 1999 Mar; 28(3 Suppl):13-8. PubMed ID: 10193998
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The use and safety profile of non-steroidal antiinflammatory drugs among Turkish patients with osteoarthritis.
    Yilmaz H; Gürel S; Ozdemir O
    Turk J Gastroenterol; 2005 Sep; 16(3):138-42. PubMed ID: 16245223
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Coxibs: highly selective cyclooxygenase-2 inhibitors. Part II. Side effects].
    Burdan F; Korobowicz A
    Pol Merkur Lekarski; 2003 Apr; 14(82):352-5. PubMed ID: 12868201
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current perspective on the cardiovascular effects of coxibs.
    Konstam MA; Weir MR
    Cleve Clin J Med; 2002; 69 Suppl 1():SI47-52. PubMed ID: 12086293
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Need for common internal controls when assessing the relative efficacy of pharmacologic agents using a meta-analytic approach: case study of cyclooxygenase 2-selective inhibitors for the treatment of osteoarthritis.
    Lee C; Hunsche E; Balshaw R; Kong SX; Schnitzer TJ
    Arthritis Rheum; 2005 Aug; 53(4):510-8. PubMed ID: 16082648
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Update on cyclooxygenase inhibitors: has a third COX isoform entered the fray?
    Hersh EV; Lally ET; Moore PA
    Curr Med Res Opin; 2005 Aug; 21(8):1217-26. PubMed ID: 16083531
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Clinical data on COX-1 and COX-2 inhibitors: what possible alerts in pharmacovigilance?].
    Larousse C; Veyrac G
    Therapie; 2000; 55(1):21-8. PubMed ID: 10859997
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.